Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Biosimilars Game On: Filing Chases AbbVie's Humira

This article was originally published in Scrip

Executive Summary

After being the company whose products have been in hot pursuit by makers of biosimilars, Amgen Inc. is seeking to market one of its own, ABP 501, a biosimilar version of AbbVie Inc.'s Humira (adalimumab) – aiming to take a bite out of the nearly $13bn in annual sales the latter firm brings in for its tumor necrosis factor (TNF) blocker.